ClinicalTrials.gg

Program

narazaciclib

Also written as “HX301+/Temozolomide”, “HX301” and “Narazaciclib”.

Its studies are mostly in Glioma · Endometrial Neoplasms, led by 2 companies.

Furthest: phase 2, since Nov 21, 20244 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hangzhou Hanx Biopharmaceuticals21 open or runningphase 2since Nov 21, 2024Jan 29, 2023Dec 31, 2026phase 2 · NCT06703255
Traws Pharma22 open or runningphase 2since Jan 19, 2023Jan 29, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 29, 2021First study: phase 1 study in Solid Tumors, AdultNew to Traws PharmaTraws Pharma · NCT04739293 · 36 planned · United States
  2. Jan 19, 2023Phase 2 study in Endometrioid Endometrial CancerTraws Pharma · NCT05705505 · 60 planned · United States
  3. Jan 29, 2023Hangzhou Hanx Biopharmaceuticals's first study: phase 1 study in Advanced Solid TumorsNew to Hangzhou Hanx BiopharmaceuticalsHangzhou Hanx Biopharmaceuticals · NCT05731934 · 20 enrolled · China
  4. Nov 21, 2024Phase 2 study in GliomaHangzhou Hanx Biopharmaceuticals · NCT06703255 · 72 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in GliomaHangzhou Hanx Biopharmaceuticals · NCT06703255

TargetBeta

“An orally bioavailable inhibitor of NUAK family SNF1-like kinase 1 (AMPK-related protein kinase 5; ARK5), and the cyclin-dependent kinases 4 (CDK4) and 6 (CDK6), ”NCIt, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06703255Glioma · China2RecruitingHangzhou Hanx BiopharmaceuticalsDec 31, 202672
NCT05731934Advanced Solid Tumors · China1CompletedHangzhou Hanx BiopharmaceuticalsJan 12, 202420
NCT05705505Endometrioid Endometrial Cancer · United States2RecruitingTraws PharmaJan 202660
NCT04739293Solid Tumors, Adult · United States1RecruitingTraws PharmaOct 202436

How it is read

Names in the registry

  • “HX301+/Temozolomide”, 1 entry
  • “HX301”, 1 entry
  • “Narazaciclib”, 1 entry
  • “ON123300”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.